The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits
JAMA · 2024
DOI: 10.1001/jama.2024.16432 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2024. Verfasst von Rita Rubin. Beteiligte Einrichtung: Lead Senior Staff Writer, Medical News & Perspectives, JAMA. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Drug Treatment, Antiviral Agents, Post-Acute COVID-19 Syndrome. Die Arbeit wurde bisher 7-mal zitiert (Crossref).
Abstract (Originalsprache)
This Medical News article discusses the latest research about the use of nirmatrelvir-ritonavir, sold as Paxlovid, to treat COVID-19 and, possibly, to prevent or treat long COVID.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lead Senior Staff Writer, Medical News & Perspectives, JAMA.
Zitieren
APA
Rubin, R. (2024). The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits. JAMA. https://doi.org/10.1001/jama.2024.16432
Vancouver
Rubin R. The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits. JAMA. 2024. doi:10.1001/jama.2024.16432
BibTeX
@article{Rubin2024,
author = {Rubin, Rita},
title = {The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2024.16432}
}
EUVIMED